Our research is geared towards identifying emerging innovation trends (and gaps) for new and repurposed medicines in clinical development pipeline that addresses unmet needs in the health system. We also engage in research to improve our methods and tools using big data analytics to gain efficiencies in our processes.
Our team of researchers and analysts actively contribute to various research projects that span across (and beyond) our core areas of interest. We have strong links and collaborations with research groups across Newcastle University, as well as academic/research institutions outside Newcastle University. We are able to support research projects at undergraduate, masters, doctoral and post-doctoral levels.
Our broad research themes and interests covers the following areas:
- Advanced methods in enhanced horizon-scanning and monitoring processes
- Pipeline and trends analysis of innovative medicines in clinical development
- Clinical trials landscape reports
- Regulatory sciences
- Orphan drugs and rare diseases
Combination therapies for COVID-19: An overview of the clinical trials landscape
In this paper, we provide an overview of the current clinical trial landscape for combination therapeutics targeting COVID-19 through weekly scanning of national and international clinical trial registries. Our analysis delves specifically into dual combination therapies in what can be defined as “pivotal clinical trials” (active, randomised, controlled and at least phase II), with a focus on new and repurposed therapeutic candidates that have shown positive signals and/or been granted authorisation for emergency use based on positive efficacy and safety data.Visit Website
Repurposing of therapeutics for SARS-CoV-2 an overview of current evidence
There is a need for effective and accessible treatments for SARS-CoV-2 and repurposing drugs already approved for other indications may provide a rapid alternative to de-novo drug development. This report provides a rapid evidence overview (evidence map and narrative synthesis) of the drug repurposing preclinical research landscape (in vivo, in vitro and in silico studies) […]Download
OP223 A Semi-Automated Process To Monitor The Clinical Development And Regulatory Approval Pathway Of Innovative Medicines
An active monitoring framework using pre-defined predictive criteria has previously been developed. This framework provides a standardized and consistent process, but is highly resource-intensive, requiring manual review of individual rEarly identification of innovative medicines is crucial for timely health technology assessment (HTA) and efficient patient access. The National Institute for Health Research Innovation Observatory (NIHRIO) […]Visit Website